Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Moodys
McKesson
Express Scripts
McKinsey

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,737,168

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,737,168 protect, and when does it expire?

Patent 7,737,168 protects TPOXX and is included in one NDA.

This patent has twenty-eight patent family members in ten countries.

Summary for Patent: 7,737,168
Title:Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Abstract: Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases cased by the orthopoxvirus.
Inventor(s): Jordan; Robert (Corvallis, OR), Bailey; Thomas R. (Pheonixville, PA), Rippin; Susan R. (Wilmington, DE)
Assignee: Siga Technologies, Inc. (Corvallis, OR)
Application Number:10/561,153
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 7,737,168

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Siga Technologies TPOXX tecovirimat CAPSULE;ORAL 208627-001 Jul 13, 2018 RX Yes Yes   Start Trial   Start Trial TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,737,168

PCT Information
PCT FiledJune 18, 2004PCT Application Number:PCT/US2004/019552
PCT Publication Date:December 29, 2004PCT Publication Number: WO2004/112718

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
AstraZeneca
Medtronic
Mallinckrodt
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.